ABSTRACT: A novel molecular scaffold has been synthesized, and its incorporation into new analogues of biologically active molecules across multiple target classes will be discussed. In these studies, we have shown use of the tricyclic scaffold to synthesize potent inhibitors of the serine peptidase DPP-4, antagonists of the CCR5 receptor, and highly potent and selective PI3K δ isoform inhibitors. We also describe the predicted physicochemical properties of the resulting inhibitors and conclude that the tractable molecular scaffold could have potential application in future drug discovery programs.
■ INTRODUCTION
The search for new molecular scaffolds, amenable to expansion by parallel synthesis techniques, is an important challenge for synthetic medicinal chemists. 1 From our ongoing studies, 2−4 into designing such scaffolds, 5−8 we were drawn to the possibility of generating a series of readily functionalized compounds with well-defined conformations that provide points of diversity expansion for parallel substitution methods. Central to our scaffold design strategy was the growing evidence that nitrogen containing saturated heterocycles, fused to substituted heterocyclic rings, are present in many druglike molecules. 9−12 In our design strategy, we wanted to combine this growing privileged motif within a tricyclic ring system containing a substituted 1,2,4-triazole ring. This would allow us to examine geometric isomerism (cis-and trans-ring fusion), the dihedral angle of the ring junction, and the influence of absolute chirality on biological activity. We therefore considered that the substituted tricyclic ring systems would be ideal candidates to synthesize and evaluate across multiple biological targets (Figure 1) .
In order to assess the utility of the tricyclic ring system as a new privileged scaffold, we were drawn to the exciting possibility of substituting the tricyclic scaffold into known biologically active compounds to compare both the resulting pharmacological activity and their predicted physicochemical parameters. From the outset of the project, we were interested in designing a novel molecular entity that, when appropriately functionalized, would possess potent activity and robust structure activity relationships (SARs) without being promiscuous. 13 In addition, we wanted the new compounds to be "druglike" with respect to their predicted physicochemical properties. 1,14−16 In order to test our hypothesis, we examined drug case histories where X-ray structural information was available to allow molecular docking experiments to guide our design strategies. As an outcome, we chose to incorporate the scaffold into three distinct series of compounds targeting; a serine protease (dipeptidyl peptidase-4, DPP-4), a G proteincoupled receptor (CCR5 receptor antagonist), and a kinase inhibitor (phosphoinositide 3-kinase, PI3K δ). We report here our initial findings in this area of privileged scaffold design, demonstrating potent cross-target biological activity of the resulting functionalized compounds combined with excellent predicted physicochemical properties.
■ RESULTS AND DISCUSSION
We recently communicated the synthesis and evaluation of new DPP-4 inhibitors based on the tricyclic scaffold, 17 and we now report further structure activity relationships (SARs) of this interesting new class of potent DPP-4 inhibitors, demonstrating the utility for incorporation into druglike molecules ( Figure 2 ).
Type-2 diabetes is a chronic disease, characterized by elevated blood sugar levels, leading to severe vascular complications and an increased mortality risk, and it is now well recognized that inhibition of the widely distributed serine protease dipeptidyl peptidase-4 (DPP-4) is a clinically validated target for antidiabetic therapy. 18 Sitagliptin was the first approved DPP-4 inhibitor launched by Merck in 2006, 19 and this was followed recently by omarigliptin, 20 a once weekly treatment for type-2 diabetes. Most recently, several series of structurally diverse DPP-4 inhibitors have been communicated demonstrating that the search for new compounds is still an important goal for both pharmaceutical companies and academic groups ( Figure 3 ). 21−23 We previously demonstrated that cis-fused diastereoisomers (1, 2) were more potent inhibitors than the corresponding trans-fused diastereoisomers (3, 4) . A preference was observed for one of the resolved cis-diastereoisomers, although at the time of initial disclosure we could not determine the absolute chirality of the cis-eutomer (Table 1) .
To determine the absolute stereochemistry of the resolved diastereoisomers (1 and 2), we embarked on a diastereomeric synthesis, as we were unable to obtain crystals of sufficient quality for single crystal X-ray structural analysis. Catalano et al. recently published 24 the stereoselective synthesis of 1-substituted cyclic ketone 7 using the stereoselective reduction of imine 6 generated from (S)-1-(4-methoxyphenyl)ethan-1-amine and δ keto ester 5 (Scheme 1).
Following literature precedent, we attempted to generate imine 9 from reaction of (S)-1-(4-methoxyphenyl)ethan-1-amine and δ keto ester 8. However, we were unable to generate the resulting imine even after heating under Dean−Stark conditions for several days. We therefore opted for the more routine reductive amination reaction stirring (S)-1-(4-methoxyphenyl)ethan-1-amine and δ keto ester 8 in 1,2-dichlorethane in the presence of sodium triacetoxy borohydride. 25 From the literature precedent, we predicted that the reductive amination using (S)-1-(4-methoxyphenyl) ethan-1-amine would generate diastereoisomer 2, which had previously been predicted through molecular docking to be the less-active diastereoisomer. 17, 26 The reductive amination reaction proceeded to afford 10 in 20% yield. Catalytic transfer hydrogenation removed the 4-methoxybenzyl group, affording the cyclized bicyclic lactam 11, as a separable 5:1 mixture of cis-to trans-isomers. The cis-fused isomer 11 was converted to thiolactam 12 through treatment with Lawesson's reagent. The thiolactam 12 was converted into the corresponding tricyclic triazole 13 by refluxing in toluene with 2,2,2-trifluoroacetohydrazide. The carbamate protecting group was removed to afford the key molecular scaffold 14, which was reacted with (R)-3-((tert-butoxycarbonyl)amino)-4-(2,4,5-trifluorophenyl)butanoic acid to generate 2, after removal of the protecting group (Scheme 2).
The final product (containing a mixture of 1 and 2) was analyzed by chiral HPLC, which showed two isomers: 2 (93%) and 1 (7%). From the literature precedent, we concluded that the stereoselective synthesis had generated the less biologically active diastereoisomer (Figure 4 ), thus demonstrating that the eutomer was most likely isomer 1? However, further detailed work needs to be undertaken to demonstrate the precedentbased assignment of stereochemistry, and this work will be reported in due course.
To understand the observed differences seen in DPP-4 inhibitory activity for the isomers, docking studies were carried out with the crystal structure of sitagliptin in DPP-4 (PDB code 1X70). 19, 26 It has been known that the primary amine present in sitagliptin has strong ionic interactions with E 205 , E 206 , and Y 662 and π-stacking with Y 662 all of which have been shown to be conserved within the compounds (1, 2) . In addition, sitagliptin has further electrostatic and van der Waals interactions with S 207 , F 357 , and R 358 in the S2 pocket and a further hydrogen bonding interaction, through a water molecule, to Y 547 ( Figure 5a) . 19 From the molecular docking experiments, it was shown that the more active cis-fused diastereoisomer 1 maintained the strong interactions with S 207 , F 357 , and R 358 but had suboptimal hydrogen bonding interaction with Y 547 (Figure 5b ). This might explain the small reduction in activity of 1 when compared to sitagliptin. Similarly, 2 was shown to lack the hydrogen bonding interactions with Y 547 , S 207 , and R 358 (Figure 4c ), suggesting a likely rationale for the observed differences seen in DPP-4 inhibitory activity between 1 and 2.
Due to the convergent synthesis, it was possible to rapidly synthesize a range of analogs (40−47) which were prepared in a similar fashion to those already reported (1−4) (Scheme 3).
The known bicyclic thioamides (15, 16) 17,27 were reacted with a range of substituted acyl hydrazides (R 1 CONHNH 2 ) to give tricyclic triazoles (17−23) , which were deprotected to the corresponding N−H piperidines (24−31) in refluxing KOH in aqueous ethanol. The resulting piperidines (24−31) were reacted with (R)-3-((tert-butoxycarbonyl)amino)-4-(2,4,5-trifluorophenyl)butanoic acid to give, after deprotection, the corresponding analogs (40−47). Through substituting the group R 1 , an interesting structure activity relationship (SAR) was revealed within this class of new DPP-4 inhibitors ( Table 2) .
Once more, the cis-fused diasteroisomer 41 proved more active that the trans-fused diastereisomer 47. It is encouraging to note that R 1 substitution, with either small alkyl groups (40, 41) or heterocycles (44−46), gave compounds with high DPP-4 inhibitory activity, while larger groups (42, 43) led to a reduction in DPP-4 inhibitory activity. This suggested a steric requirement for the R 1 substituent within the DPP-4 active site. This is most notable when considering the 3-ethoxypyrid-2-yl 43 and 2-pyridyl 44 analogues, which shows that an increase in (a) Analytical chiral HPLC analysis of the final mixture of products, containing 2 (93%) and 1 (7%); (b) sample spiked with the previously separated, eutomer 1. Phenomenex LC Lux 5u Amylose-2 packed column (250 × 4.6 mm) at a flow rate of 1.5 mL/min, using 70% hexane: 30% ethanol supplemented with 0.2% diethylamine over 30 min.
size results in a 3-fold reduction in DPP-4 inhibitory activity. This can be rationalized through considering the docking of 43, which showed a possible steric clash of the ethoxyl group with S 209 in the active site ( Figure 6 ). 26 One of our success criteria was that the resulting compounds should be lead-like with respect to their physicochemical properties. 15, 16, 28 As a metric to demonstrate lead-likeness, we chose to evaluate the lipophilic ligand efficiency (LIPE) 11,29−31 of our most potent analogues and compare them to sitagliptin (Table 3) .
It was gratifying to note that 40 displayed very good predicted druglike characteristics (LIPE 6.9), comparing favorably to sitagliptin. Further analysis showed 40 to have a favorable topological polar surface area (TPSA) 33 value of 77 Å 2 and high predicted solubility in water (calculated solubility at pH 7.4: 5.39 mg/mL, sitagliptin: 3.20 mg/mL).
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Having demonstrated that the molecular scaffold was capable of generating compounds with excellent biological activity balanced with good calculated lead-like physicochemical properties against one target class, we chose to look at designing a series of GPCR receptor antagonists. In our second case study, we chose the chemokine receptor CCR5 as the biological target, as we were drawn to the structural similarity between the tricyclic ring system and the corresponding group present in the CCR5 receptor antagonist, maraviroc ( Figure 7) .
The CCR5 receptor is a chemokine receptor, which is located on the cell surface of T cells and can bind specific peptide ligands called chemokines and belong to a large family of the seven transmembrane GPCRs. The human CCR5 receptor itself is a 352 amino acid protein and consists of seven transmembrane spanning helices connected through three extracellular loops (ECL1, ECL2, and ECL3), three intracellular loops, an extracellular N-terminus, and an intracellular C-terminus and N-terminus functionality. The extracellular loops and transmembrane helices are responsible for binding ligands, and the intracellular regions are responsible for signal transduction. The activation of the chemokine receptor CCR5 through its binding of endogenously expressed chemokines (macrophage inflammatory proteins MIP-1α and MIP-1β as well as "regulated on activation, normal T cell expressed, and secreted" RANTES) can cause typical cellular responses, including inhibition of cAMP production or stimulation of intracellular Ca
2+
. 34 CCR5 is a coreceptor for HIV entry into T cells, and maraviroc is the only marketed CCR5 receptor antagonist for R5 HIV therapy to date. 35, 36 While our chemical design appears a rational "fast-follower" process, we were concerned that the tropane ring present in maraviroc had been shown to give a 40-fold increase in affinity compared to the piperidine analogue. 37 In addition, the triazole group in maraviroc adopts a conformation where it is orthogonal to the tropane ring, whereas in our proposed analogue the triazole group would be occupying a different spatial configuration. As a consequence of these considerations, we decided to generate a receptor model based on the reported maraviroc-bound X-ray crystal structure of CCR5 and examined the overlay and key receptor interactions of our proposed analogues to that of maraviroc ( Figure 8) . 26 In the molecular docking, it was shown that a very good overlay to maraviroc was observed with the cis-fused diastereoisomer 48. In addition, key hydrogen bonding interactions were seen to T 195 , T 259 , Y 251 , E 283 , and Y 37 and strong face-to-face interaction with W 86 -interactions was reported for maraviroc. 38 In light of the positive docking results, we proceeded to embark on a synthesis of the maraviroc analogues, using an analogous route to the previously reported synthesis (Scheme 4). Unfortunately, the final compounds could not be separated into single diastereoisomers, and so the compounds were screened as either a mixture or separated cis-or transdiastereoisomers (48−49) .
Benzyl (S)-(3-oxo-1-phenylpropyl)carbamate 39 was reacted with piperidines (24, 50) under reductive amination conditions 25 to give Cbz-protected intermediates (51a−b) which were deprotected and acylated with 4,4-difluorocyclohexane-1-carboxylic acid to generate the maraviroc analogues (48, 49) in good overall yield.
RANTES was chosen as the agonist in our biological evaluation, as receptor agonism with MIP-1α was shown to be less reproducible in our hands. This biological screen was carried out using the Ca 2+ signaling assay by testing the ability of a single concentration of antagonist [30 nM (48) or 1 μM (49), final concentration] to shift agonist (RANTES) concentration response curves, and the estimated affinity values (pK D ) 40 are summarized in Table 4 . It is interesting to note that, even though the lipophilic tropane interaction present in maraviroc was absent in 48, a very good level of CCR5 receptor antagonism was observed.
Importantly, a reduction in calculated lipophilicity and molecular weight might lead to an improvement in ADME properties? However, further research is required to demonstrate that the calculated druglike properties may lead to an improved over all profile.
Having demonstrated that the new molecular scaffold was capable of generating compounds with excellent biological activity and activity against two target classes, we chose to look at utilizing the scaffold into the design of a series of kinase inhibitors. In this approach, we wanted to use the molecular scaffold to function as a key molecular recognition group to increase kinase activity and also fine-tune kinase isoform selectivity. In this respect, we were drawn to the exciting possibility of designing a set of potent and selective phosphoinositol-3 kinase δ isoform inhibitors, an area of interest from our University of Nottingham and GlaxoSmithKline research teaching collaboration. 41 Phosphoinositol-3 kinase (PI3K) signaling plays a central role in cellular functioning, including growth, proliferation, survival, or migration. It therefore has a pivotal role in diseases such as those related to the respiratory tract, e.g. asthma 42 and cancer. 43 These lipid kinases catalyze phosphorylation, which leads to the production of phosphatidylinositol (PI(3,4,5)P3) through the isoforms α, β, γ, and δ. (PI(3,4,5)P3) is involved in the signaling of kinase Akt (protein kinase B), which is a serine/threonine protease involved in cell growth, survival, proliferation, and angiogenesis. Phosphoinositol (3,4,5)-trisphosphate (PIP3) is an important intracellular second messenger, whose biological action occurs through stimulating increase of the intracellular calcium ion concentration. The PI3 kinase family can be divided into three different classes depending on their domain structure. The main focus in current research is on the class 1 PI3Ks, which consist of four members. The majority of research is concentrated on the class 1A subunit isoforms PI3K α, PI3K β, and PI3K δ, and furthermore the class 1B subunit PI3K γ. Due to their fundamental roles, the design of selective inhibitors is important to consider, as nonselective compounds could result in toxicity. As PI3K δ expression is limited to leukocytes, its inhibition has potential for the treatment of respiratory diseases 42 and leukemia. 44, 45 The reduction of response in PI3K δ knock in (KI) mice and animals was seen after treatment with a PI3 δ specific inhibitor, which is demonstrated by reduced clonal expansion of CD4 cells and diminished pathology in asthma models. 46 The inactivation of PI3K δ also affects mast cell function, which plays an important role in allergic responses and asthma.
In this case study, we considered pictilisib, 47 a pan PI3K inhibitor, as the chemical starting point, as the X-ray crystal structure was available. 48 In addition, 52 was recently reported as a more selective PI3K δ inhibitor [PI3K α (340-fold), PI3K β (200-fold), PI3K γ (410-fold)], suggesting that PI3K δ isoform selectivity could be achieved within the thienyl pyrimidine class of PI3K inhibitors. 49 Our plan was to investigate the role for the incorporation of the molecular scaffold to synthesize a series of potent and selective PI3K δ inhibitors ( Figure 9 ).
Modest PI3K δ isoform selectivity has been reported though an edge to face interaction of the thienyl pyrimidine with W 760 the so-called tryptophan shelf interaction. 49 In addition, it is known that, even though there is good homology between the PI3K isoforms, an important residue change exists between the four isoforms that might also aid δ isoform selectivity. An overlay of the available crystal structures reveals a potential key π−cation interaction present in the structures of the α (K 750 ), β (K 771 ), and γ (K 771 ) isoforms with W 760 (δ-numbering) that is not present in PI3K δ (T 750 ). This led us to the exciting possibility that our inhibitors might be able to form an extra van der Waal π−π face to face interaction with W 760 , an interaction occluded in the case of the other isoforms (Figure 10) .
Furthermore, it has been reported that selectivity for PI3K δ can be achieved in part due to the effect of the affinity pocket group R 2 , with R 2 = 4-substituted indole giving rise to good PI3K δ isoform selectivity. 49 We therefore decided to use a small 3D matrix-based approach (18 compounds) to evaluate the potency and selectivity profiles of substituting groups R 1 , R 2 , and R 3 ( Figure 11 ). In addition, we included the open chain analogues (62−67) to evaluate the role of the tricyclic ring system on potency and selectivity.
The synthesis of the compounds (62−79) was accomplished through a two-step procedure. The acyclic intermediates (53 and 54) were prepared by the high-yielding 1,2,4-triazole synthesis method as outlined by Stocks (Scheme 5). 4 The six substituted piperidines (groups R 1 in Figure 11 ) were reacted with aldehyde 55 47 using picoline borane 51 as the reducing agent in 10% acetic acid in methanol to generate the key intermediates (56−61) that were then subjected to Suzuki−Miyaura cross-coupling reactions 52, 53 to afford compounds (62−79) in high yield (Scheme 6). Figure 9 . Potent pan PI3K inhibitor pictilisib, δ-selective PI3K inhibitor 52, and proposed inhibitors based on the tricyclic scaffold.
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The compounds were screened against PI3K isoforms, and their biological activities are reported in Table 5 . 54 It is interesting to note that all the compounds demonstrated a good degree of isoform selectivity for PI3K δ over PI3K α, PI3K β, and PI3K γ. However, the following discussion will concentrate on the PI3K δ/α isoform selectivity ( Figure 12 ).
A plot of PI3K δ potency versus PI3K α potency showed a general trend that compounds with R 2 = 4-substituted indolyl [e.g., 73 (∼4000-fold), 72, and 78 (∼2000-fold)] were more PI3K δ isoform selective 49 ( Figure 13 ). It is noteworthy that high PI3K isoform selectivity was also achieved, where R 2 = 4-indazolyl (71, δ/α ∼ 500-fold, δ/β ∼ 400-fold, δ/γ ∼ 400-fold), demonstrating that high PI3K δ isoform potency, and therefore selectivity, could be enhanced by the methyl-substituted cis-fused tricyclic molecular scaffold over the acyclic scaffold (compare 71 with 63), suggesting that our initial proposal from molecular docking studies for further interaction of the cis-fused tricyclic scaffold with W 760 may be driving the PI3K δ isoform activity and therefore selectivity independently of the known activity pocket selectivity afforded by the 4-substituted indole group. Further analysis of the role of group R 1 showed a general trend, with the tricyclic compounds showing a greater level of activity at PI3K δ than PI3K α when compared to the acyclic compounds. This is very apparent when looking at a matched-pair analysis 55 between compounds containing the acyclic scaffold (groups A) and the cis-fused tricyclic containing compounds (groups B)compare 65 with 69, 66 with 68, 63 with 71, 67 with 72, and 64 with 73. (Figure  14) . From the analysis, the matched-pairs generally have similar levels of PI3K α activity, but the inclusion of the cis-fused tricyclic ring increases the level of PI3K δ activity, with the largest difference in PI3K δ activity being observed for the matched pairs (67 and 72).
A similar profile was observed between compounds containing the acyclic scaffold (groups A) and the trans-fused tricyclic containing compounds (groups C)compare 65 with 75, 62 with 79, 66 with 74, 63 with 76, 67 with 77, and 64 with 78 ( Figure 15 ).
Further examination of group R 1 as a function of PI3K δ/α selectivity showed that the tricyclic compounds (groups B and C) give rise to a very good selectivity profile with (72, 73, and 78), showing the optimal balance between very high PI3K δ activity and selectivity over PI3K α ( Figure 16 ).
Indeed, it is very encouraging to note that compound 73 achieved a very high degree of PI3K δ selectivity over PI3K β (∼400-fold) and PI3K γ (2000-fold). To test the druglikeness of the synthesized compounds, the physicochemical properties of 73 were calculated (PI3K δ (pIC 50 = 9.1), MWt 540.7, cLogP 3.9, clogD 2.5, TPSA 88 Å 2 , solubility at pH 7.4 in water: 32 While the properties may not be ideal for oral druglikeness, the compounds may fulfill inhalation delivery criteria, where MWt appears to be less important for successful drug development. 46, 56 In addition, the compound may well prove very useful as a highly selective tool compound to further probe biological mechanisms for the role of PI3K δ in other therapies. 57−59 Within the three case histories presented, the cis-fused diastereoisomer of the tricyclic scaffold ( Figure 1 ) proved the most potent diastereoisomer. It is interesting to speculate that a common molecular recognition motif might be present in each of the biological targets, and further work is ongoing in our laboratory to explore this exciting possibility.
Implicit to the design strategy was to generate a series of new molecular entities that could be readily diversified by robust synthetic chemistry. In our considerations, it was important to ensure that the scaffolds contained sufficient functionality to allow hydrogen bonding interaction within diverse biological systems but also possessed a sufficient degree of lipophilicity to make interactions with lipophilic amino acids within the binding pockets. In our design phase, we rationalized that the optimal strategy for obtaining biological interactions in novel scaffolds was to separate the polar groups with hydrogen bond neutral linking groups and, importantly, to avoid the proximity of too many polar interactive groups that could lead to reduction in binding. We therefore suggest the following simple strategy to consider when generating new molecular scaffolds for high hit rate compound libraries, as well as for use in lead optimization programs where scaffold diversity is required:
• Examine the medicinal chemistry literature and identify core "over-represented" features in druglike molecules to 
a Potency against the different PI3K isoforms is given as pIC 50 values (n = 2). b The potency threshold for the PI3K δ assay is ∼ pIC 50 9 due to substrate concentration. enable design mimics with structural diversity, while maintaining core physicochemical properties.
• Hypothesize new ring systems containing aspects of these features (i.e., fused/spirocyclic ring systems) containing a maximum of two points of diversity, remembering the virtue of rings within medicinal chemistry design has good precedence 60 due to their higher intrinsic ligand efficiency, increased crystallinity, and reduction in degrees of flexibility (ΔG vs ΔS) compared to acyclic systems.
• Re-evaluate chemical design to remove overcomplexity and unwanted functionality to improve synthetic tractability, including stereocontrol for chiral centers, and include "simple opportunities" to modify scaffolds at a later stage.
61
• Enumerate and profile a small subset of the virtual library based on physicochemical properties and deselect scaffolds that do not offer compounds with good physicochemical properties.
1
• Generate sets of closely related scaffolds with common capping chemistries to expedite synthesis.
• Complete the library matrix to build SAR and discover serendipitous synergistic group effects.
■ CONCLUSION
In summary, we have shown the successful synthesis of promising new druglike compounds as inhibitors of DPP-4, antagonists of the CCR5 receptor, and highly selective and potent inhibitors of PI3K δ based on an interesting new molecular scaffold. Importantly, the compounds possess good predicted lead-or druglike properties, 15, 62, 32 giving extra evidence for the scaffold to be considered privileged for medicinal chemistry projects. In the DPP-4 case study, we have shown the stereochemical preference for the cis-fused diastereoisomer of the octahydro [1, 2, 4] triazolo [4,3-a] [1, 6] naphthyridine tricyclic ring system and have described initial studies toward a diastereoselective synthesis of the new molecular scaffold resulting in determination of the absolute configuration of the eutomer. Further work is ongoing in our laboratories on the incorporation of the new molecular scaffold into new compounds to interact with biological targets, and these will be reported in due course.
■ EXPERIMENTAL SECTION
ChemistryGeneral Methods. All reactions with air-and humidity-sensitive reagents were carried out under an atmosphere of nitrogen. The flasks were flushed with nitrogen. The liquids were added using plastic syringes. All starting materials, reagents and solvents were purchased from commercial suppliers e.g. Acros, SigmaAldrich, Fluorochem, Key Organics and Merck. All solvents were either analytical reagent or HPLC grade and were supplied by Fisher Scientific. Dry solvents were used for all reactions and were purchased from Sigma-Aldrich and VWR. The petroleum ether had a boiling point of 40 to 60°C. CDCl 3 was supplied by Cambridge Isotope Laboratories, Inc., MeOD 4 was supplied by Sigma-Aldrich. All reactions were monitored for completion using TLC. Therefore, commercially available precoated silica gel 60 F 254 aluminum plates from Merck were used. Visualization of the spots was carried using the UV-lamp (λ = 254 nm) and stained with KMnO 4 or iodine and subsequently heated. Flash column chromatography was carried out using silica gel, technical grade, pore size 60 Å, 230−400 mesh particle size, 40−60 μm particle size purchased from Sigma-Aldrich. The 13 Cand 1 H NMR spectra were recorded using a Bruker AV (II) 500 spectrometer with a magnetic field strength of 9.4T. This is corresponding to a resonance frequency of 400 MHz for protons and around 100 MHz for the 13 C nucleus. All The following abbreviations were used to describe signal shapes and multiplicity: s (singlet), bs (broad singlet), d (doublet), dd (doublet of doublet), ddd (doublet of doublet of a doublet), dddd (doublet of a doublet of a doublet of a doublet), t (triplet), dt (doublet of a triplet), q (quartet), dq (doublet of a quartet) and m (multiplet). Furthermore, 2D-NMR experiments: COSY and HSQC were used for the assignment of the signals and the processing of the NMR data was carried out using the NMR software TopSpin 3.0. All high-resolution mass spectra (HRMS)-time to flight electrospray were recorded on a Waters 2795 spectrometer by electrospray ionization (TOF ES) and the LC-MS spectra were performed on a Shimadzu UFLCXR system coupled to an Applied Biosystems API2000, and visualized at 220 nm (channel 2) and 254 nm (channel 1). LC-MS was carried out using a Phenomenex Gemini-NX C18 110A, column (50 mm × 2 mm x 3 μm) at a flow rate 0.5 mL/min over a 5 min period -method (A). Analytical RP-HPLC was performed using a Waters 2767 sample manager, Waters 2525 binary gradient module, and visualized at 220 nm with a Waters 2487 dual wavelength absorbance detector -method (B). Spectra were analyzed using MassLynx. Preparative HPLC was performed using a Phenomenex Gemini-NX 5u C18 110A, AXIA packed column (160 mm × 21.2 mm) at a flow rate of 20 mL/min, typically starting with 90% water/10% acetonitrile and progressing to 100% acetonitrile over 40 min. The water phase contained 0.01% ammonia. Chiral analytical HPLC was performed using a Phenomenex LC Lux 5u Amylose-2 packed column (250 × 4.6 mm) at a flow rate of 1.5 mL/min, isocratically using 70% hexane: 30% ethanol supplemented with 0.2% DEA over 30 min -method (C).
All compounds submitted for biological screening had a purity >95% determined through either methods (A), (B) or (C).
General Procedure 1,2,4-Triazole Formation. To a solution of ethyl 2-thioxooctahydro-1, 6-naphthyridine-6(2H)-carboxylate (15 and 16) (2.43 mmol, 1 equiv) in toluene (20 mL) was added the corresponding hydrazide (4.86 mmol, 2 equiv) and the mixture was refluxed at 110°C for 48 h. The solvent was evaporated and the crude product was purified by flash chromatography (dichloromethane/ methanol 10:1) to yield the substituted triazoles (17−23).
General Procedure for the Removal of the Carbamate Protecting Group. To a solution of the protected substituted triazole (17−23, 0.41 mmol, 1 equiv) in ethanol (0.44 mL) and water (2.50 mL) was added KOH (1.80 mmol, 2.0−4.4 equiv) and the mixture was refluxed at 110°C for 20 h. The reaction mixture was extracted with DCM (10 mL). The organic phase was dried over MgSO4, filtered and the solvent was evaporated and the crude product was used without further purification.
( (20 mL) . The water phase was extracted with ethyl acetate (3 × 20 mL). The combined organic phases were washed with saturated aqueous sodium chloride (20 mL), dried over Na 2 SO 4 , filtered and the crude product was purified by flash chromatography (dichloromethane/methanol: 10:1) to yield the amide.
General Method for boc-Deprotection. To the above amides (32-39, 0.08 mmol, 1 equiv) was added 4 N HCl in 1,4-dioxane (0.5 mL) and the reaction mixture was stirred at RT for 30 min. The excess hydrogen chloride solution was evaporated under N 2 gas to yield the hydrochloride salt of the amines as oils. (48) . To a solution of CBz protected amine 51a (200 mg, 0.4 mmol, 1 equiv) in methanol (7 mL) was added Pd/C and the reaction was stirred under an atmosphere of hydrogen overnight. The crude product was filtered through Celite and the solvent was evaporated under reduced pressure.
rel-tert-Butyl ((R)-4-((5S
To 4,4-difluorocyclohexane-1-carboxylic acid (38 mg, 0.2 mmol, 1.5 equiv) in DMF (3.5 mL) was added DIPEA (56 μL, 0.3 mmol, 3.0 equiv), HATU (50 mg, 0.13 mmol, 1.2 equiv) and amine (50 mg, 0.15 mmol, 1.0 equiv). The reaction was stirred at RT for 2h. and was diluted with water (10 mL). The aqueous phase was extracted with ethyl acetate (3 × 10 mL) and the combined organic phases were washed with saturated aqueous ammonium chloride (10 mL), dried over Na 2 SO 4 , filtered and the solvent was evaporated under reduced pressure. The crude product was purified by flash chromatography (dichloromethane/methanol 20:1) to yield amine 48 (68 mg, 33%) as a white solid after further purification using preparative HPLC. 1 (49) . To a solution of CBz protected amine 51b (97 mg, 0.2 mmol, 1.0 equiv) in methanol (1 mL) was added Pd/C and the reaction was stirred under an atmosphere of hydrogen overnight. The crude product was filtered through Celite and the solvent was evaporated under reduced pressure. To difluorocyclohexane-1-carboxylic acid (20 mg, 0.12 mmol, 1.5 equiv) in DMF (2.5 mL) was added DIPEA (33 μL, 0.24 mmol, 3.0 equiv), HATU (37 mg, 0.1 mmol, 1.2eq) and amine (26 mg, 0.1 mmol, 1.0 equiv). The reaction was stirred at rt for 2h and was diluted with water (10 mL). The aqueous phase was extracted with ethyl acetate (3 × 10 mL) and the combined organic phases were washed with saturated aqueous ammonium chloride (10 mL), dried over Na 2 SO 4 , filtered and the solvent was evaporated under reduced pressure. The crude product was purified by flash chromatography (dichloromethane/methanol 20:1) and SCX column chromatography (dichloromethane to methanol to 7N ammonia in methanol) to yield amine 49 (9 mg, 24%) as a white solid after further purification using preparative HPLC. 200 mg, 1.0 mmol, 1.7 equiv) . The reaction was stirred overnight and. the crude reaction mixture was diluted with saturated aqueous sodium bicarbonate (25 mL). The aqueous phase was extracted with ethyl acetate (3 × 25 mL). The combined organic phases were dried over Na 2 SO 4 , filtered and the solvent was evaporated under reduced pressure. The crude product was purified by flash chromatography (dichloromethane/methanol, 10:1) to give 51a (40 mg, 57%) as a colorless oil, which was further purified by preparative HPLC.
HPLC: (t R = 15.2 min, 97%, method (B)). The reaction was stirred overnight and the crude reaction mixture was diluted with saturated aqueous sodium bicarbonate (10 mL). The aqueous phase was extracted with ethyl acetate (3 × 25 mL). The combined organic phases were dried over Na 2 SO 4 , filtered and the solvent was evaporated. The crude product was purified by flash chromatography (petrol ether/ethyl acetate, 2:1) to give the product 51b (217 mg, 57%) as colorless oil, which was further purified by preparative HPLC.
HPLC (t R = 14.41 min, 98%, method (B)). tert-Butyl 4-(3-Methyl-4H-1,2,4-triazol-4-yl)piperidine-1-carboxylate (53) . Acetic hydrazide (0.814 g) was dissolved in acetonitrile (2 mL) and dimethylformamide dimethyl acetal (1.31 g) was added. The mixture was heated to 50°C for 30 min and then N-1 boc-4-aminopiperidine (1.00 g) was added followed by acetic acid (1 mL). The reaction was heated to 100°C for 20 h and was cooled and concentrated. The residue was partitioned between ethyl acetate (20 mL) and saturated sodium bicarbonate (20 mL) and was extracted into ethyl acetate (2 × 20 mL). The combined extracts were dried (MgSO4), filtered and concentrated. The residue was purified by chromatography on silica gel eluting with 0.7 N ammonia in methanol in dichloromethane (1/9) to give the product (1.15 g, 86%) as an oil. General Procedure for Reductive Amination Reaction. A stirred solution of 2-chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde (1.1 mmol, 1.1 equiv) and corresponding substituted piperidine (e.g., 24, 1 mmol, 1 equiv) in methanol (9 mL) and acetic acid (1 mL) was heated to 40°C for 1 h. and cooled to room temperature where picoline borane (1.5 mmol, 1.5 equiv) was added and the resulting reaction was stirred at room temperature for 20 h. The reaction mixture was concentrated and partitioned between dichloromethane (10 mL) and saturated sodium hydrogen carbonate (10 mL). The mixture was extracted with dichloromethane (2 × 15 mL) and the combined extracts were dried (MgSO 4 ), filtered and concentrated. The residue was purified by chromatography on silica gel eluting with 2 to 10% methanol (containing 0.7N ammonia) in dichloromethane to afford the product.
4-(2-Chloro-6-((4-(3-methyl-4H-1,2,4-triazol-4-yl)piperidin-1-yl)-methyl)thieno [3,2- Enzyme: DPP4 recombinant human protein was purchased from Sino Biological Inc. Substrate: H-Gly-Pro-AMC was purchased from Bachem Americas, Inc. Assay buffer (100 mM Hepes, pH 7.5) was prepared by HitGen. All chemical reagents used were of analytical reagent grade. Assay protocol: Prepare 10 mM compound stock solution in DMSO. The initial rate of DPP4 activity is measured over 15 min by monitoring the fluorescent change (ex/em =360/460 nm). The fits are inspected to ensure that the reactions are linear to a correlation coefficient of 0.9. IC 50 values are calculated by fitting percent remaining activity vs log (inhibitor concentration) using fourparameter dose−response model (Sigmaplot Version 11.0).
CCR5 Receptor Antagonism Assay. The transfection for the generation of the HEK 293 Glosensor cells stably expressing CCR-5 was carried out using CCR-5 plasmid obtained from the cDNA.org library (CCR050TN00) and Lipofectamine according to the manufacturers' instructions. Transfected cells were subjected to selective pressure for 2−3 weeks through the addition of 1 mg.mL −1 G418.HEK 293 Glosensor cells expressing CCR-5 with a density of 2.5 × 10 4 cells/mL were placed in each well of a 96 well black plate (100 μL) were incubated at 37°C, 5% CO 2 for 48 h prior to the assay. On the day of experiment the medium was aspirated and replaced with assay buffer prepared by adding glucose (90 mg) and BSA (50 mg) to 50 mL 1 x HBSS and probenecid solution (180 mg probenecid, 1.25 mL 1 M NaOH and 1.25 mL assay buffer, 500 μL) (complete assay buffer). The complete assay buffer (10 mL) was supplemented by 23 μL Fluo-4 dye (prepared by adding 23 μL DMSO and 23 μL pluronic acid 20% in DMSO to Fluo-4 AM) (Fluo-4 buffer). Fluo-4 buffer (100 μL) was added to each well of the black walled plate and incubated at 37°C for 45 min. Antagonist (compound) solutions were prepared by either a single concentration (300 nM (48) or 10 μM (49) in complete assay buffer) The Fluo-4 buffer was aspirated and the cells were washed (x2) with complete assay buffer. Complete assay buffer (100 μL) was added to the wells and 10 μL of the corresponding concentration of the antagonist was added in triplicate and incubated for 30 min at 37°C to give final concentrations of 30 nM or 1 μM. Agonist concentrations for the dose response curve were prepared as serial dilutions with final concentrations of 100 nM −1 nM in half logs (RANTES). Agonist concentrations (20 μL) were added in triplicate into a clear 96 well plate and were added directly prior to the measurement. The wells were screened on the Flexstation 1 (Molecular Devices) by measuring intracellular calcium by monitoring the change in fluorescence every 2s for 5 min. The estimated affinity value for each antagonist (pK D ) was calculated from the shift of the agonist dose response curve brought about by addition of a single concentration of antagonist (30 nM or 1 μM) using the Gaddum equation as previously described.
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PI3K Inhibition Assay. Inhibition of PI3K α, -β, -γ, and -δ enzymatic activity was determined using a homogeneous time-resolved fluorescence (HTRF) kit assay format provided by Millipore. 54 Molecular DockingGeneral Methods. The three-dimensional coordinates of the cocrystal structure of sitagliptin in the active site of DPP4 (pdb code 1 × 70), the cocrystal structure of maraviroc in the active site of the chemokine receptor CCR-5 (pdb code 4MBS) and the crystal structure of PI3K δ in complex with pictilisib (pdb code 2WXP) were retrieved from the Protein Data Bank. 64 All nonprotein atoms, including water and sugar molecules were removed from the model. Using MAKE RECEPTOR 3.0.0 software (OpenEye Scientific Software) an active site model was prepared for each active site (DPP-4, CCR5, PI3K δ) being considered. No constraints were used during this preparation of the receptor model. A database composed of suggested compounds for docking and the reference ligands [sitagliptin (DPP-4), maraviroc (CCR5), pictilisib (PI3K δ)] and the newly designed compounds were processed with the Omega 2.5.1.4 software (OpenEye Scientific Software, Inc.,) to generate the 200 lowest energy conformations for each compound. Finally, the compounds were docked into the active site models using the FRED 3.0.1 software and the Chemgauss4 scoring function (OpenEye Scientific Software, Inc.,). The docking was visually analyzed for the top 5 best scored poses for the conformation of the designed compounds using VIDA 4.3.0 and outputs visualized using PyMOL (The PyMOL Molecular Graphics System, Version 1.8 Schrodinger, LLC). The poses were visually compared with the cocrystallized reference ligand and the best overlaying docking pose has been presented in this manuscript.
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